Concepedia

Igor Feldman

IF

Statistics

Publications

13

Citations

2.5K

H-Index

12

Active since

2003

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Moderna Therapeutics (United States)

Epizyme (United States)

Harvard University

Columbia University

Igor Feldman is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, molecular oncology, and life sciences.

ORCID

Publications per year

2003–2024

13

Publications

13

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak et al. · The Lancet · 2024 · 739 citations

, , +14

An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies

Jennifer O’Neil, Yair Benita, Igor Feldman et al. · Molecular Cancer Therapeutics · 2016 · 432 citations

, , +13

Network properties of genes harboring inherited disease mutations

Igor Feldman, Andrey Rzhetsky, Dennis Vitkup · Proceedings of the National Academy of Sciences · 2008 · 296 citations · Full text

, , +16

Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

Amy D. Guertin, Jing Li, Yaping Liu et al. · Molecular Cancer Therapeutics · 2013 · 171 citations

, , +17

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <i>In Vitro</i> and <i>In Vivo</i> Preclinical Models

Elayne Chan-Penebre, Kelli Armstrong, Allison E. Drew et al. · Molecular Cancer Therapeutics · 2017 · 168 citations

, , +17

1–5 of 13